Full-Year Financial Results Presentation for the Fiscal Year Ending March 2026 | JMDC Inc. (4483) timely disclosure

Worth reading

57In focus

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Mixed performance

Direction inferred from the company’s description.

Scale

% (year-on-year change in consolidated revenue, operating profit and EBITDA)

Wording

Avoiding a definitive answer

How definitive the wording is.

Contents of this document

Financial results presentationFiscal year ending March 2026, full year8 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales¥50,462 million+21.0%

Operating profit¥10,521 million+21.0%

Ordinary income¥9,964 million +17.0%profit before tax, IFRS

Net income¥6,765 million +16.0%profit attributable to owners of the parent, continuing operations

Operating profit margin21 %0.0%

Results for the three months of the current quarter

Consolidated revenue

¥13,973 million

Consolidated EBITDA

¥3,496 million

Health big data revenue

¥12,440 million

Health big data EBITDA

¥3,779 million

Telemedicine revenue

¥1,672 million

Telemedicine EBITDA

¥684 million

Full-year earnings forecast

Revenue

¥60,500 million

Operating profit

¥11,500 million

Income before taxes

¥11,000 million

Profit attributable to owners of the parent

¥7,100 million

EBITDA

¥15,000 million

What the company explained in this material

Self-assessment against the planThe company's self-assessment against its own plan.

Revenue was broadly in line with guidance, but profit fell short of plan

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

Addressing issues associated with the expansion of data assets and missed business opportunities with the medical divisions of pharmaceutical companies¥-920 million
Growth investments, including new business development for pharmaceutical companies and AI investment¥-400 million

Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.

Health big data growth
DetailsSustain growth across all business areas, primarily in the industry segment
Telemedicine growth
DetailsModerate growth supported by solid demand while maintaining high profitability
M&A
DetailsFuture M&A not included in the assumptions
Investment
DetailsInvest in an AI platform, including sales, data assets, human resources and data infrastructure

New initiatives

Reinforce sales resources and strengthen the business serving the medical divisions of pharmaceutical companies
Strategic investment in an AI platform, including human resources and data infrastructure
Projects including AI RWD analysis tools, support for medical representative activities, clinical-trial digital transformation and drug-discovery efficiency improvements
Development of an AI disease-risk prediction model with OMRON

Key KPIsA metric the company considers important as a management benchmark.

Number of insured persons covered by contracted health insurance societies2,076 10,000 people
Number of Pep Up IDs803 10,000 people
Year on year against the same period last year+24.0%
Market share in the municipal-government sector50 Around %
Number of local governments1,716 Local government
Number of systems provided to medical institutions3,600 Approx. hospitals
Number of hospitals authorized to use data1,500 Approx. hospitals
Number of contracted medical institutions1,665 Facility
Number of contracted radiologists1,255 people
Telemedicine industry market share30 Approximately %

Segment results

Health Big Data

Sales

¥44,070 million+24.0%

EBITDA

¥11,722 million+23.0%

EBITDA margin

27 %

Telemedicine

Sales

¥6,392 million+4.0%

EBITDA

¥2,407 million+8.0%

EBITDA margin

38 %

Adjustments

EBITDA

¥-952 million

Market Size / Share

Market share in the municipal-government sector50 Around %
Telemedicine industry market share30 Approximately %
Number of medical facilities in Japan11 Approx. 10,000 facilities
Annual number of diagnostic imaging examinations1.5 100 million cases
Number of radiologists6,000 People, approximately

Annual Dividend

Fiscal year ending March 2026

Annual Dividend¥18 per share

End of period¥18 per share

Forecast for the fiscal year ending March 2027To be determined

Contents of this document
Item	Details
Document type	Financial results presentation
Fiscal Period Covered	Fiscal year ending March 2026, full year
Net Sales	¥50,462 million (YoY +21.0%)
Operating profit	¥10,521 million (YoY +21.0%)
Ordinary income	¥9,964 million (profit before tax, IFRS) (YoY +17.0%)
Net income	¥6,765 million (profit attributable to owners of the parent, continuing operations) (YoY +16.0%)
Operating profit margin	21 % (YoY 0.0%)
Results for the three months of the current quarter	Consolidated revenue ¥13,973 million / Consolidated EBITDA ¥3,496 million / Health big data revenue ¥12,440 million / Health big data EBITDA ¥3,779 million / Telemedicine revenue ¥1,672 million / Telemedicine EBITDA ¥684 million
Full-year earnings forecast	Revenue ¥60,500 million / Operating profit ¥11,500 million / Income before taxes ¥11,000 million / Profit attributable to owners of the parent ¥7,100 million / EBITDA ¥15,000 million
Self-assessment against the plan	Revenue was broadly in line with guidance, but profit fell short of plan
Segment results	Health Big Data Sales ¥44,070 million (YoY +24.0%) / EBITDA ¥11,722 million (YoY +23.0%) / EBITDA margin 27 % / Telemedicine Sales ¥6,392 million (YoY +4.0%) / EBITDA ¥2,407 million (YoY +8.0%) / EBITDA margin 38 % / Adjustments Sales Not disclosed / EBITDA ¥-952 million
Breakdown of Factors Affecting the Change	Factors Addressing issues associated with the expansion of data assets and missed business opportunities with the medical divisions of pharmaceutical companies / Amount ¥-920 million, Factors Growth investments, including new business development for pharmaceutical companies and AI investment / Amount ¥-400 million
Key KPIs	Number of insured persons covered by contracted health insurance societies 2,076 10,000 people, Number of Pep Up IDs 803 10,000 people, Market share in the municipal-government sector 50 Around %, Number of local governments 1,716 Local government, Number of systems provided to medical institutions 3,600 Approx. hospitals, Number of hospitals authorized to use data 1,500 Approx. hospitals, Number of contracted medical institutions 1,665 Facility, Number of contracted radiologists 1,255 people, Telemedicine industry market share 30 Approximately %
Assumptions Underlying the Business Outlook	Item Health big data growth / Details Sustain growth across all business areas, primarily in the industry segment, Item Telemedicine growth / Details Moderate growth supported by solid demand while maintaining high profitability, Item M&A / Details Future M&A not included in the assumptions, Item Investment / Details Invest in an AI platform, including sales, data assets, human resources and data infrastructure
Annual Dividend	Fiscal year ending March 2026 Annual Dividend ¥18 per share / Interim Not disclosed / End of period ¥18 per share / Forecast for the fiscal year ending March 2027 To be determined
Market Size / Share	Market share in the municipal-government sector 50 Around %, Telemedicine industry market share 30 Approximately %, Number of medical facilities in Japan 11 Approx. 10,000 facilities, Annual number of diagnostic imaging examinations 1.5 100 million cases, Number of radiologists 6,000 People, approximately
New initiatives	Reinforce sales resources and strengthen the business serving the medical divisions of pharmaceutical companies, Strategic investment in an AI platform, including human resources and data infrastructure, Projects including AI RWD analysis tools, support for medical representative activities, clinical-trial digital transformation and drug-discovery efficiency improvements, Development of an AI disease-risk prediction model with OMRON

Items this document does not state (14)

Gross Profit MarginSelling, general and administrative expensesProgress against full-year forecastUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The factors behind the shortfall in profit for the fiscal year ended March 2026 included addressing data-processing issues associated with the expansion of data assets, missed business opportunities with the medical divisions of pharmaceutical companies, and growth investments such as new business development for pharmaceutical companies and AI investment. Regarding the business serving the medical divisions, the Company explained that customer delivery was delayed because data processing required more work than expected, while the volume of proposals was insufficient because sales resources were prioritized for other divisions.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.